Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) covers the month of June 2017, with the report signed on June 7, 2017. The filing discloses a new issue of unlisted options under the company's Employee Incentive Scheme (ESOP) and Consulting Agreements. The registrant is a foreign private issuer based in Australia.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margin, or debt figures. It focuses exclusively on capital structure changes related to the issuance of options.
- Ordinary Shares on Issue: 533,891,470 Fully Paid Ordinary Shares.
- New Securities Issued: 8,550,000 Unlisted Options.
- Exercise Price: AUD$0.07 per option.
- Expiry Date: June 6, 2022.
- Consideration: Nil cash consideration (issued under ESOP).
- Total Unlisted Options: 26,826,063 (including the new issue and existing tranches).
Material Changes Versus Prior Period
The primary material change is the issuance of 8,550,000 new unlisted options. These securities were issued under an exception in ASX Listing Rule 7.2. The filing indicates that no securities were issued without security holder approval under Rule 7.1, nor were any issued with specific approval under Rule 7.1A or 7.3 during the relevant period. The new options rank equally with existing quoted securities upon exercise into Ordinary Shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It is a regulatory disclosure of a capital event. The document notes that the entity is an "eligible entity" that obtained security holder approval under Rule 7.1A on November 17, 2016, which facilitates the issuance of securities under specific exceptions. No specific risks or contingencies are detailed beyond the standard regulatory requirements for the option issue.
Investor Verification Checklist
- Verify the total number of outstanding options (26,826,063) and their respective exercise prices to assess potential dilution.
- Confirm the remaining placement capacity under ASX Rules 7.1 (80,083,721 shares) and 7.1A (53,389,147 shares) as calculated in Annexure 1.
- Review the terms of the Employee Incentive Scheme to understand vesting conditions attached to the 8,550,000 new options.
- Note that the filing does not contain financial performance data; refer to the most recent Form 20-F or ASX announcements for revenue and cash flow metrics.